dangers of glp 1 drugs The GLP-1 Agonists and Obesity: How Diabetes are Changing Non-Diabetic Lives — tl;dr pharmacy The promise and peril of

While they are not FDA-approved themselves, they provide an alternative pathway for those who need personalized dosing under a providers care

Nausea Often Happens During Dose Escalation Many people notice nausea when they first start the medication or when their dose increases

In May 2023, the FDA approved Mounjaro (tirzepatide) injection by Eli Lilly and Company for adults suffering from type 2 diabetes to improve glycemic control

Side effects are common , particularly when first starting treatment

Physiologic replacement of both these incretin agents in the form of dual GLP-1/GIP receptor activating compounds (twincretins) has yielded encouraging results vis--vis glucose and body weight regulation

You finally took the plunge and started taking a GLP-1 drug to improve your health